European regulators have ordered the recall of all batches of Amgen’s Tavneos (avacopan) after the European Commission canceled its marketing authorization earlier this month. The recall action is described as a follow-on to the Commission’s formal decision. The announcement indicates that regulators are moving to manage the consequences of the canceled authorization, including risk mitigation for patients and compliance steps for distribution channels. For companies with EU reliance, these actions underscore that marketing authorization cancellations can rapidly translate into inventory-level interventions, regardless of prior clinical use. Developers of similar rare-disease or immunology assets are likely to watch closely for the cause of cancellation and any pathway for re-authorization, as well as potential implications for ongoing label usage across member states.